ReviewDiagnostics (Basel, Switzerland)2022
Screening for Liver Fibrosis in the General Population: Where Do We Stand in 2022?
Review in Diagnostics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- Prevalence of clinically significant liver fibrosis in the general population: A systematic review and meta-analysis.Clinical and molecular hepatology · 2024Pooled it
- Urinary collagen type I degradation products as common fibrosis biomarkers in chronic diseases.Molecular medicine (Cambridge, Mass.) · 2026Article
- Harnessing artificial intelligence for the assessment of liver fibrosis and steatosisWorld journal of gastroenterology · 2026Review
- The Relationship Between FIB-4 Score and Dynapenia in Older Adults.Diagnostics (Basel, Switzerland) · 2025Article
- Avian Influenza: Outbreak in Viet Nam in 2024.Infectious disorders drug targets · 2025Article
- An Alternative Non-Invasive Screening Model for Liver Fibrosis among US Adults at Risk of MASLD.Diseases (Basel, Switzerland) · 2024Article
- Ultrasound Shear Wave Elastography Evaluation of the Liver and Implications for Perioperative Medicine.Journal of clinical medicine · 2024Review
- The Impact of Silent Liver Disease on Hospital Length of Stay Following Isolated Coronary Artery Bypass Grafting Surgery.Journal of clinical medicine · 2024Article
- Article
- Serum biomarkers for liver fibrosis assessment.Advances in laboratory medicine · 2024Review
- Performance Evaluation of a Novel Non-Invasive Test for the Detection of Advanced Liver Fibrosis in Metabolic Dysfunction-Associated Fatty Liver Disease.Metabolites · 2024Article
- Prevalence of hepatic steatosis and fibrosis in apparently healthy airline pilots: A transient elastography study.Hepatology forum · 2024Article
- Prevalence and Crucial Parameters in Diabesity-Related Liver Fibrosis: A Preliminary Study.Journal of clinical medicine · 2023Article
- Diagnostic Performance of Biomarker-Based Scores as Predictors of Metabolic Dysfunction-Associated Fatty Liver Disease Risk in Healthy Children.Nutrients · 2023Article
- Exploring the Correlation Between Vitamin D Levels and Serological Markers in Liver Diseases: Insights from a Cross-Sectional Study.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Approximately 30% of the worldwide population has at least one risk factor for liver disease. Identifying advanced liver disease before the occurrence of complications remains a difficult challenge in clinical practice, where diagnosis comes too late for many patients, at the time of liver decompensation or palliative hepatocellular carcinoma, with poor short-term prognosis. Noninvasive, blood- or elastography-based tests of liver fibrosis (NITs) have been developed for the early diagnosis of advanced liver fibrosis. Recent population-based studies evaluating the screening of liver fibrosis with these NITs have provided important information on at-risk groups that should be targeted. New measures based on the sequential use of NITs help to better organize the referral of at-risk patients to the liver specialist. However, energizing these measures will require increased awareness of both chronic liver diseases and the use of NITs among non-specialists.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.